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Background: Increasing evidence showed that miRNAs serve as modulators of human cancer, either as oncogene
or tumor suppressors. Cisplatin resistance is the most common cause of chemotherapy failure in gastric cancer (GC).
However, the roles of miRNAs in cisplatin resistance of GC remain largely unknown. The aim of the study was to
identify a novel miRNA/gene pathway that regulates the sensitivity of GC cells to cisplatin.
Methods: In this study, we chose miR-223 by qRT-PCR analysis, the most significantly up-regulated miRNA in GC, to
investigate its formation of DDP-resistant phenotype of GC cells and possible molecular mechanisms.
Results: We found that miR-223 was most significantly up-regulated miRNA in DDP-resistant GC cells compared
with parental GC cells. Besides, its expression was also significantly up-regulated in GC tissues. FBXW7 was identified
as the direct and functional target gene of miR-223. Overexpression of FBXW7 could mimic the effect of miR-223
down-regulation and silencing of FBXW7 could partially reverse the effect of miR-223 down-regulation on DDP
resistance of DDP-resistant GC cells. Besides, miR-223 and FBXW7 could affect the G1/S transition of cell cycle by altering
some certain cell cycle regulators. Furthermore, miR-223 was found to be significantly up-regulated in H. pylori infected
tissues and cells, suggesting that H. pylori infection may lead to GC development and DDP resistance.
Conclusions: Our findings revealed the roles of miR-223/FBXW7 signaling in the DDP resistance of GC cells and
targeting it will be a potential strategic approach for reversing the DDP resistance in human GC.
Keywords: miR-223, FBXW7, Cisplatin resistance, Gastric cancerIntroduction
Gastric cancer (GC) is the second leading cause of
cancer-related deaths worldwide [1]. With an overall 5-
year survival rate of only 20%, it becomes a major cause
of both morbidity and mortality, where even resectable
disease has a 50-90% risk of recurrence and death [2].
However, therapies often fail due to cancer cell multi-
drug resistance (MDR), which tends to develop after the
initial rounds of treatment or before treatment begins
(intrinsic MDR) [3]. The molecular mechanism under-
lying single or multidrug resistance to chemotherapeutic* Correspondence: guoxinz@njmu.edu.cn
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unless otherwise stated.agents is complex and involves increases in drug efflux,
insensitivity to drug-induced apoptosis and the enhance-
ment of drug detoxification [4]. Although great efforts
have been made to understand the mechanism under-
lying multidrug resistance, the current knowledge re-
mains limited [5].
MicroRNAs (miRNAs) are a large class of endogenous
non-coding RNAs, 21–23 nucleotides in length that
regulate about 30% of human gene expression [6]. MiR-
NAs can function post-transcriptionally through imper-
fect base pairing with specific sequences in the 3’
untranslated regions (UTRs) of target mRNAs, leading
to transcript degradation or translational inhibition [7].
Increasing evidence has shown that miRNAs have crit-
ical roles in the control of various human biological pro-
cesses, such as development, angiogenesis, apoptosis and
differentiation [8]. Increasing researches have shown thehis is an Open Access article distributed under the terms of the Creative
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anticancer drug resistance and miRNAs expression pro-
filing can be correlated with the development of drug
resistance, suggesting that the miRNAs-mediated form
of drug resistance adds another molecular mechanism of
drug resistance [9]. A couple of recent studies have
reported the role of miRNAs in modulating GC or other
tumor chemoresistance. Zhang et al. showed that miR-
106a could promote chemoresistance of cisplatin resist-
ant human GC cells by targeting RUNX3 [10]. Shang
et al. showed that miR-508-5p could reverse chemoresis-
tance of GC cells by targeting ABCB1 and ZNRD1 [11].
Zhou et al. identified that miR-33a is up-regulated in
chemoresistant OS and that the miR-33a level is nega-
tively correlated with the TWIST protein level [12].
These studies provided initial clues for miRNAs in regu-
lating GC chemoresistance.
In the present study, we demonstrated that miR-223
could promote DDP resistance of GC cells via regulating
G1/S cell cycle transition and apoptosis by targeting
FBXW7. Thus, this report identifies novel signaling
pathways and molecules as potential therapeutic targets
for the treatment of DDP-resistant human GCs.
Materials and methods
Patients and samples
A total of 50 pairs of tumor and adjacent tissues were
collected from GC patients who performed gastrectomy
prior to any treatment at the First Affiliated Hospital of
Nanjing Medical University during October 2013 and
September 2014. The basic characteristics of the en-
rolled patients were listed in Additional file 1: Table S1.
For the use of materials for research purposes, written
informed consent was obtained from each patient. The
consent procedure and study protocol were approved by
the Medical Institutional Ethical Committee of first affil-
iated hospital of Nanjing Medical University.
Cell culture and transfection
SGC-7901 and BGC-823 and their respective resistance
cells were purchased from Shanghai Institute of Cell
Biology (Shanghai, China). All cell lines were cultured in
RPMI 1640 (GIBCO, Rockville, MD, USA) medium sup-
plemented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 mg/ml streptomycin in humidified air
at 37°C with 5% CO2. MiR-223 mimic or inhibitor or
siRNA-FBXW7 and their negative controls were ob-
tained from GenePharma (Shanghai, China). The open
reading frame of FBXW7 that was generated by PCR
was then inserted into the pcDNA 3.1 expression vector,
which was named pcDNA-FBXW7. The recombinant
vector was confirmed by the digestion analysis of restric-
tion endonuclease and DNA sequencing. For ectopic ex-
pression of miR-223, miR-223 mimic or miR-NC vectorswere purchased from GenePharm. The transfection
was performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the instructions.
Quantitative real-time PCR
Total RNA was isolated using TRIzol reagent. The spe-
cific RT primers used were: miR-223:5’-GTCGTATC-
CAGTGCGTGTCGTGGAGTCGGCAATTGCACTGG
ATACGACAACTCA-3’ and U6:5’-CGCTTCACGAAT
TTGCGTGTCA-3’. RT was performed using Prime-
Script™ RT reagent Kit (Takara, Otsu, Japan) according
to the manufacturer’s instructions. PCR primers used
were: miR-223 sense, 5’-CCGCTCGAGGAGCTTCCA
GCTGAGCACTGGG-3’ and antisense, 5’-CGACGCG
TTATTGCGCCCCCATCAGCACT-3’; U6 sense, 5’-
CTCGCTTCGGCAGCACA-3’ and antisense, 5’-AAC
GCTTCACGAATTTGCGT-3’; FBXW7 Forward, 5’-
GTCCCGAGAAGCGGTTTGATA-3’; Reverse, 5’-TG
CTCAGGCACGTCAGAAAAG-3’; GAPDH sense, 5’-
GCACCGTCAAGGCTGAGAAC-3’ and antisense, 5’-
TGGTGAAGACGCCAGTGGA-3’. QRT-PCR was per-
formed using SYBR Premix ExTaq (TaKaRa, Dalian,
China) according to the manufacturer’s protocol.
Western blot assay
The cells were lysed using the mammalian protein ex-
traction reagent RIPA (Beyotime, Beijing, China). Ap-
proximately a 50 μg protein extraction was separated by
10% SDS-PAGE, transferred to 0.22 mm nitrocellulose
(NC) membrane (Sigma), and incubated with specific
antibodies. Autoradiograms were quantified by densi-
tometry using Quantity One software (Bio-Rad, CA,
USA). β-actin (diluted 1:1000) antibody was used as a
control and rabbit anti-FBXW7 (1:1000 dilution), p14
(1:100 dilution), p16 (1:100 dilution), p21 (1:150 dilu-
tion), p27 (1:50 dilution), CDK2 (1:200 dilution), CDK4
(1:100 dilution), CDK6 (1:100 dilution), c-myc (1:150
dilution), CCND1 (1:100 dilution), CCND2 (1:150 dilu-
tion), CCND3 (1:100 dilution), CCNE1 (1:150 dilution),
CCNE2 (1:50 dilution) were provided by Cell Signaling
Technology (MA, USA).
In vitro chemosensitivity assay
The in vitro chemosensitivity assay was determined by
MTT assay. Briefly, cells were seeded into 96-well plates
(3.5 × 103 cells/well) and allowed to attach overnight.
Cells were then treated with various concentrations of
DDP. At 24 h, cell vitality was assessed using 0.5 mg/mL
MTT (Sigma, MO, USA) solution. Approximately 4 h
later, the medium was replaced with 150 μl dimethyl
sulfoxide (DMSO, Sigma, MO, USA) and vortexed for
10 min. The absorbance at 490 nm (A490) of each well
was read using a spectrophotometer. Each experiment
was performed in triplicate.
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Cells were trypsinized to single cell suspensions and
were seeded 6-well plates at 500/well. After 14 days cul-
ture in RPMI 1640 medium with FBS, the colonies were
stained with crystal violet solution and the number of
colonies was counted. Each experiment was performed
in triplicate.
Luciferase reporter assay
A FBXW7-3’UTR luciferase reporter was created. Briefly,
the 3’UTR sequence of FBXW7 predicted to interact with
miR-223 was amplified and cloned into the EcoRI and
XhoI sites of pGL3-luc vector (Promega, Madison, WI,
USA). The site-directed mutagenesis of the miR-223
target-site was carried out using Invitrogen (Californlia,
USA). The constructs were sequenced and named
pGL3-luc-FBXW7/3’-UTR-wt or pGL3-luc-FBXW7/3’-
UTR-mut. For reporter assays, SGC-7901 cells were
cultured in 24-well plates and each transfected with
100 ng of pGL3-luc-FBXW7/3’UTR-wt or pGL3-luc-
FBXW7/3’UTR-mut and miR-223 mimics or inhibitor
using Lipofectamine 2000 (Invitrogen, USA). 48 hours
after transfection, cells were harvested and assayed with
Dual-Luciferase Reporter Assay kit (Promega, USA) ac-
cording to the manufacturer’s instructions.
Flow cytometric analysis of cell cycle and apoptosis
For apoptosis analysis, cells were treated with various
concentrations of DDP for 24 h, harvested and fixed
with 2.5% (v/v) glutaraldehyde for 30 min. The rate of
apoptosis was determined using Annexin V-FITC and PI
staining by flow cytometry. For cell cycle analysis, cells
were treated with various concentrations of DDP for
24 h, washed with ice-cold PBS and fixed with 70% (v/v)
ethanol overnight at −20°C. Fixed cells were rehydrated
in PBS for 10 min and subjected to PI/RNase staining
followed by flow cytometric analysis using a FACScan
instrument (Becton Dickinson, Mountain view, CA, US)
and CellQuest software (Becton Dickinson, San Jose,
CA, US).
Statistical analysis
All experimental data were expressed as the Mean ± S.D.
The significance of differences of clinical data according
to miR-223 expression was determined by Student’s
t-test. All analyses were performed with SPSS 17.0 (SPSS
Inc, Chicago, IL, USA) for Windows. The significance
level was set at P < 0.05.
Results
MiR-223 is up-regulated in tumor tissues and DDP-
resistant GC cells
To determine the correlation of dysregulated miRNAs
with DDP resistance, frequently reported miRNAs relatedto GC were chosen to distinguish the difference between
resistance and sensitivity of GC cells [13-22]. We detected
the IC50 of sensitive and resistance cells first and found
that the IC50 of 7901/DDP (Figure 1A) or BGC-823/DDP
(Figure 1B) was significantly higher than that in respective
sensitive cells. Then, we found that a panel of miRNAs
was dysregulated in 7901/DDP cells compared with 7901
cells. Among the 10 miRNAs, miR-223 was found to be
most significantly changed in 7901/DDP cells (P < 0.01)
(Figure 1C). The result was similar in another GC cell line
(P < 0.01; Figure 1D). We co-cultured 7901 and BGC-823
cells with different MOIs of H. pylori and found that miR-
223 expression increased with MOIs of H. pylori infection
(Additional file 2: Figure S1A). We also detected miR-223
expression in tumor and control tissues and found that
miR-223 expression was significantly higher in tumors
(Figure 1E, p < 0.05) and it expressed especially higher in
stage III/IV patients (Figure 1F, p < 0.05). We further di-
vided the patients into H. pylori infected and non-infected
groups and found that miR-223 was significantly higher in
H. pylori infected tumor and control adjacent tissues
(Additional file 2: Figure S1B). Taken together, these data
suggested that up-regulation of miR-223 might have im-
portant roles in the development of GC and DDP resist-
ance in GC cells, especially under H. pylori infection state.
Effect of miR-223 expression on sensitivity of GC cells to
cisplatin in vitro
To investigate the roles of miR-223 in the DDP resist-
ance, miR-223 inhibitor or inhibitor NC (iNC) was tran-
siently transfected into 7901/DDP and BGC-823/DDP
cells. Forty-eight hours after transfection, qRT-PCR
assay was performed and indicated that miR-223 expres-
sion was significantly decreased after inhibitor transfec-
tion (p < 0.05) (Figure 2A). Then, we determined the
effect of miR-223 inhibitor on colony formation of 7901/
DDP cells when exposed to DDP treatment (0 and 4 ug/
ml). As shown in Figure 2B and Additional file 2: Figure
S1C, the capacity of colony formation in miR-223 inhibi-
tor transfected 7901/DDP and BGC-823/DDP cells was
significantly decreased compared with iNC transfected
cells (p < 0.05). The IC50 value of DDP in miR-223
inhibitor transfected 7901/DDP or BGC-823/DDP cells
was also significantly reduced substantially (p < 0.05).
Meantime, the IC50 value in miR-223 inhibitor trans-
fected 7901/DDP or BGC-823/DDP cells still showed
higher levels than that in respective sensitive cells,
suggesting that inhibiting miR-223 expression could only
partially reverse the DDP-resistant GC cells to DDP-
sensitive phenotype (Figure 2C). Next, we analyzed the
effects of miR-223 inhibitor on cell cycle and apoptosis
of 7901/DDP cells when exposed to DDP treatment by
flow cytometry. Compared with iNC transfected cells,
the percent of 7901/DDP or BGC-823/DDP cells in G0/
Figure 1 miR-223 expression in cells and tissues. (A) The IC50 level of 7901 and 7901/DDP; (B) The IC50 level of BGC-823 and BGC-823/DDP;
(C) qRT-PCR detection of differential miRNAs expression in 7901 and 7901/DDP cells; (D) qRT-PCR detection of differential miRNAs expression in
BGC-823 and BGC-823/DDP cells; (E) qRT-PCR detection of miR-223 in tumor and control tissues; (F) qRT-PCR detection of miR-223 in different
stages of tumor tissues. (*p < 0.05, **p < 0.01).
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while cells in S phase was decreased with different doses of
DDP (Figure 2D). Also, miR-223 could significantly in-
crease DDP-induced apoptosis of resistant cells (Figure 2E).
Therefore, down-regulation of miR-223 could reverse the
DDP resistance of resistant GC cells by inducing cell arrest
in G0/G1 phase and enhanced apoptosis when exposed to
DDP treatment.
We further investigated the role of miR-223 over-
expression on sensitive cells. We transient transfected
miR-223 mimic or NC into 7901 or BGC-823 cells. qRT-
PCR assay confirmed the up-regulated expression level
of miR-223 in 7901/miR-223 and BGC-823/miR-223
cells, compared with that in 7901/NC or BGC-823/NCcells (Figure 3A). When exposed to DDP treatment (0 or
2 ug/ml), the capacity of colony formation in 7901/miR-
223 or BGC-823/miR-223 cell was increased (p < 0.05)
(Figure 3B and Additional file 2: Figure S1D). Compared
with that in control cells, the IC50 value of DDP in
7901/miR-223 or BGC-823/miR-223 cells was increased
(Figure 3C). Next, we analyzed the effects of miR-223
up-regulation on cell cycle and apoptosis of parental GC
cells when exposed to DDP treatment by flow cytometry.
Compared with control cells, the percent of 7901/miR-
223 or BGC-823/miR-223 cells in G0/G1 phase decreased
and the percentage of cells in S phase increased with dif-
ferent doses of DDP (Figure 3D). The apoptosis of 7901/
miR-223 or BGC-823/miR-223 cells was significantly
Figure 2 Down-regulation of miR-223 significantly increases the sensitivity of 7901/DDP cells to DDP. (A) Forty-eight hours after transfection
with miR-223 inhibitor or inhibitor NC, qRT-PCR detection of miR-223 expression in cells. U6 was used as an internal control; (B) 7901/DDP cells
transfected with miR-223 inhibitor show more DDP sensitivity than cells transfected with inhibitor NC. Indicated miR-223 inhibitor or inhibitor
NC-transfected 7901/DDP cells were plated in triplicate and exposed to DDP (0.0 and 4.0ug/ml). The forci formation was indicated; (C) MTT ana-
lysis of the IC50 values of DDP in miR-224 inhibitor- or inhibitor NC-transfected 7901/DDP and parental 7901 cells; (D) Flow cytometric analysis of
cell cycle in inhibitor NC- or miR-224 inhibitor-transfected 7901/DDP cells combined with DDP (0.0 and 4.0 ug/ml); (E) Flow cytometric analysis of
apoptosis in miR-224 inhibitor- or inhibitor NC-transfected 7901/DDP combined with DDP (0.0 and 4.0 ug/ml); Data are expressed as the mean ±
S.D. of three individual experiments. *p < 0.05.
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could increase the in vitro resistance of 7901 or BGC-823
cells to DDP.
FBXW7 was a functional target of miR-223
It is known that miRNAs exert their function by dysre-
gulating their target genes expression. Thus, miR-223can perform its resistance promoting function by inhi-
biting tumor suppressor targets. The targets of miR-223
were predicted through three publicly available algo-
rithms (TargetScan, PicTar and miRanda), and FBXW7
was selected as a putative target in all three software. To
determine whether the 3’UTR region of FBXW7 mRNA
is a direct functional target of miR-223, we cloned
Figure 3 Up-regulation of miR-223 significantly reduces the sensitivity of 7901 cells to DDP. (A) qRT-PCR detection of miR-223 expression
in miR-223 mimic or NC-tranfected 7901 cells. U6 was used as an internal control; (B) 7901/miR-223 cells show less DDP sensitivity than 7901/NC
cells. Indicated 7901/miR-223 or 7901/NC cells were plated in triplicate and exposed to DDP (0 and 2.0 ug/ml). The forci formation was indicated;
(C) MTT analysis of the IC50 values of DDP in 7901/miR-224 or 7901/NC cells; (D) Flow cytometric analysis of cell cycle in 7901/miR-223 or 7901/
NC cells combined with DDP (0 and 2.0 ug/ml); (E) Flow cytometric analysis of apoptosis in 7901/miR-223 or 7901/NC cells combined with DDP
(0 and 2.0 ug/ml); Data are expressed as the mean ± S.D. of three individual experiments. (*p < 0.05, **p < 0.01).
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:28 Page 6 of 14FBXW7 3’UTR containing the potential binding site into
the pGL3 vector to generate the pGL3-FBXW7-wt vec-
tor (Figure 4A). The luciferase activity was determined
after co-transfecting pGL3-FBXW7-wt vector and miR-
223 mimic or NC and the result showed that the lucifer-
ase activity was decreased by miR-223 mimics transfec-
tion (P < 0.05) when the wild type 3’UTR of FBXW7 was
present, and the activity was increased significantly (P <
0.05) when miR-223 was inhibited. No difference wasfound when transfecting with pGL3-FBXW7-mut vector
(Figure 4B). Then, qRT-PCR and western blot assays were
performed to analyze the effects of miR-223 expression
change on FBXW7 mRNA and protein expression. The
results showed that FBXW7 expressed significantly lower
when transfecting with miR-223 mimic and higher when
transfecting with miR-223 inhibitor, compared with re-
spective controls (Figure 4C). Western blot assay showed
similar results (Figure 4D). Therefore, miR-223 could
Figure 4 MiR-223 binds to the 3’UTR of FBXW7 mRNA. (A) Sequence of the miR-223-binding site within the FBXW7 3’UTR (190–197 bp)
predicted with TargetScan and miRBase. Mutation was generated on the FBXW7 3’UTR sequence in the complementary site for the seed region
of miR-223. A FBXW7 3’UTR fragment containing wild-type or mutant miR-223-binding sequence was cloned downstream of the luciferase reporter
gene in pGL3-luc vector; (B) Relative luciferase activity was analyzed after wild-type or mutant 3’UTR reporter plasmids were co-transfected with miR-
224 mimic or inhibitor in 7901 cells. The histogram shows the mean ± S.D. of the normalized luciferase activity from three independent experiments;
(C) qRT-PCR detection of FBXW7 mRNA expression in 7901 cells transfected with miR-223 mimic or inhibitor. GAPDH was used as an internal control;
(D) Western blot detection of FBXW7 protein expression in cells transfected with miR-223 mimic or inhibitor. β-actin was used as an internal control.
Data are expressed as the mean ± S.D. of three individual experiments. *p < 0.05.
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targeting FBXW7 3’UTR transcript.
To further investigate the roles of FBXW7 in DDP re-
sistance, pcDNA/FBXW7 or pcDNA/NC was transiently
transfected into 7901/DDP cells. Both qRT-PCR and
western blot assays confirmed that the expression of
FBXW7 mRNA and protein was significantly increased in
7901/DDP/FBXW7 cells (Figure 5A). Compared with
7901/DDP/NC cells, the IC50 value of DDP to 7901/DDP/
FBXW7 cells was decreased significantly (Figure 5B). Flow
cytometric analysis of cell cycle indicated that the percent
of 7901/DDP/FBXW7 cells in G0/G1 phase of cell cycle
increased and the percentage of cells in S phase decreased
with different doses of DDP (Figure 5C). The increased
apoptosis was observed in 7901/DDP/FBXW7 cells when
exposed to different doses of DDP treatment (Figure 5D).These data indicated that FBXW7 up-regulation could
increase the sensitivity of 7901/DDP cells to DDP. Further,
we determined whether the up-regulation of FBXW7
could rescue the effects of miR-223 over-expression on
the chemosensitivity of GC cells. qRT-PCR and western
blot assays confirmed that pcDNA/FBXW7 could rescue
the expression of FBXW7 mRNA and protein (Additional
file 3: Figure S2A). Also, up-regulation of FBXW7 could
rescue the increased IC50 value of DDP to 7901 cells in-
duced by miR-223 over-expression (Additional file 3: Figure
S2B). In addition, up-regulation of FBXW7 could reverse
the effects of miR-223 overexpression on the G1/S
transition (Additional file 3: Figure S2C) and DDP-
induced apoptosis (Additional file 3: Figure S2D) of
7901 cells. Thus, up-regulation of FBXW7 could mimic
the effect of miR-223 down-regulation on the chemo
Figure 5 Over-expression of FBXW7 could mimic the effect miR-223 inhibitor on the sensitivity of 7901/DDP cells. (A) qRT-PCR and
western blot detection of FBXW7 mRNA and protein expression in 7901/DDP/NC or 7901/DDP/FBXW7 cells; (B) MTT analysis of the IC50 values of
DDP in 7901/DDP/NC or 7901/DDP/FBXW7 cells; (C) Flow cytometric analysis of cell cycle in 7901/DDP/NC or 7901/DDP/FBXW7 cells combined
with DDP (0 and 2.0 ug/ml); (D) Flow cytometric analysis of apoptosis in 7901/DDP/NC or 7901/DDP/FBXW7 cells combined with DDP (0 and 2.0
ug/ml). Results represent the average of three independent experiments (mean ± S.D.). *p < 0.05.
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miR-223 overexpression on the chemo sensitivity of
7901 cells.Finally, FBXW7 siRNA was transiently transfected into
7901 cells. Forty-eight hours after transfection, qRT-PCR
and western blot assays showed that FBXW7 expression
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fected cells (Figure 6A). Also, the IC50 value of DDP to
7901/siRNA/FBXW7 cells was increased compared with
that to 7901/siRNA/control cells (Figure 6B). When 7901Figure 6 siRNA-mediated down-regulation of FBXW7 could mimic eff
eight hours after transfection with siRNA/FBXW7 or siRNA/NC, qRT-PCR and w
analysis of the IC50 values of DDP in siRNA/NC or siRNA/FBXW7-transfected 79
FBXW7-transfected 7901 cells combined with DDP (0 and 2 ug/ml); (D) Flow
7901 cells combined with DDP (0 and 2 ug/ml). Data are expressed as the mecells were transfected with siRNA/FBXW7 combined with
DDP treatment, flow cytometry was performed to detect
cell cycle and apoptosis. Cell cycle analysis showed that
siRNA mediated FBXW7 down-regulation could lead toect of miR-223 up-regulation on sensitivity of 7901 cells. (A) Forty-
estern blot detection of FBXW7 mRNA and protein expression; (B) MTT
01 cells; (C) Flow cytometric analysis of cell cycle in siRNA/NC or siRNA/
cytometric analysis of apoptosis in siRNA/NC or siRNA/FBXW7-transfected
an ± S.D. of three individual experiments. *p < 0.05.
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rate of 7901 cells when exposed to different doses of DDP
treatment (Figure 6C). Compared with that in 7901/
siRNA/control cells, the decreased apoptosis was observed
in 7901/siRNA/FBXW7 cells when exposed to different
doses of DDP treatment (Figure 6D). Thus, siRNA/
FBXW7 could decrease the sensitivity of 7901 cells to
DDP. We further determined whether FBXW7 down-
regulation could rescue the effects of miR-223 down-
regulation on the chemo sensitivity of 7901/DDP cells.
Forty-eight hours after siRNA/FBXW7 and miR-223
inhibitor were co-transfected into 7901/DDP cells, qRT-
PCR and western blot assays showed that siRNA/FBXW7
could recover the expression of FBXW7 mRNA and pro-
tein (Additional file 4: Figure S3A). Also, siRNA/FBXW7
could decrease the increased IC50 value of DDP to 7901/
DDP cells induced by miR-223 inhibitor (Additional
file 4: Figure S3B), and siRNA/FBXW7 could abrogate
the effects of miR-223 inhibitor on the G1/S transition
(Additional file 4: Figure S3C) and DDP-induced apop-
tosis (Additional file 4: Figure S3D) of 7901/DDP cells.
Thus, down-regulation of FBXW7 could mimic the
effect of miR-223 mimic on the chemo sensitivity of
7901 cells and rescue the effect of miR-223 inhibitor
on the chemo sensitivity of 7901/DDP cells.MiR-223 and FBXW7 regulate the expression of G1/S
transition in DDP-resistant GC cells
To further investigate the roles of FBXW7 in the miR-
223-regulated cell cycle in DDP-resistant 7901 cells, weFigure 7 Western blot detection of cell cycle-related protein expressi
223 inhibitor or pcDNA/FBXW7, cells were collected. Western blot detectio
c-myc, CCND1, CCND2, CCND3, CCNE1 and CCNE2). β-actin protein was us
three individual experiments.analyzed the expression of G1/S checkpoint related pro-
teins in miR-223 inhibitor or pcDNA/FBXW7 transfected
7901/DDP cells, including CCND1, CCND2, CCND3,
CCNE1, CCNE2, CDK2, CDK4, CDK6, p14, p16, p21,
p27, c-myc (Figure 7). The expression of CDK2, CDK4,
CDK6, CCND1, CCND2 and CCND3 was significantly
down-regulated in miR-223 inhibitor or pcDNA/FBXW7-
transfected 7901/DDP cells compared with control cells,
while p14, p16, p21 and p27 were significantly up-
regulated. However, the expression of c-myc, CCNE1 and
CCNE2 showed no obvious difference between transfected
cells and control cells. Our results indicated that miR-223
and FBXW7 might affect the G1/S transition of cell cycle.Expression of miR-223 was negatively correlated with
FBXW7 expression in cells and tissues
We detected the expression level of FBXW7 mRNA in
sensitive and resistant cells and found that FBXW7
expressed significantly lower in 7901/DDP or BGC-
823/DDP cells (Figure 8A). The result was the same
that FBXW7 expression was significantly lower in GC
tissues compared with controls (Figure 8B). The rela-
tion between FBXW7 expression and clinicopathologi-
cal features was listed in Additional file 5: Table S2.
When we divided the patients into early and late stage,
we found that the expression of FBXW7 was signifi-
cantly lower in stage III/IV patients (Figure 8C). Then,
we correlated FBXW7 with miR-223 expression in the
same GC cells and specimens. A significant inverse cor-
relation was observed (2-tailed Spearman's correlation,on. Forty-eight hours after 7901/DDP cells were transfected with miR-
n of cell cycle-related proteins (p14, p16, p21, p27, CDK2, CDK4, CDK6,
ed as an internal control. Data are expressed as the mean ± S.D. of
Figure 8 Expression of miR-223 was negatively correlated with FBXW7 in cells and tissues. (A) qRT-PCR detection of FBXW7 mRNA in
7901 and BGC-823 and their respective resistant cells; (B) qRT-PCR detection of FBXW7 mRNA in tumor and control tissues; (C) qRT-PCR detection
of FBXW7 mRNA in different stages in tumor tissues; (D) A statistically significant inverse correlation between miR-223 and FBXW7 mRNA levels in 15
cases of GC tissues. (Spearman’s correlation analysis, r = −0.915, p = 0.000). Data are expressed as the mean ± S.D. of three individual experiments.
Corresponding P values analyzed by Spearman correlation test are indicated.
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:28 Page 11 of 14
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:28 Page 12 of 14r = −0.915; P = 0.000) when FBXW7 mRNA levels were
plotted against miR-223 expression (Figure 8D).
Discussion
Cisplatin (DDP), a DNA damaging chemical, has been
for many years used as a systematic chemotherapeutic
agent for several human tumor types, including GC. It
could increase cell death and apoptosis, arresting cells in
G0/G1 phase [23]. Unfortunately, intrinsic or acquired
tumor cell resistance to DDP severely limits its thera-
peutic efficacy. Multiple mechanisms have been pro-
posed for the development of DDP resistance in GC,
including the reduced intracellular accumulation of the
drug, increased levels of glutathione and anti-apoptotic
proteins, and decreased pro-apoptotic proteins [24].
Growing evidence has shown that miRNAs have regula-
tory roles in the pathogenesis of malignant tumors,
through the suppression of genes involved in cell growth,
differentiation, development, apoptosis, metastasis and
chemo- or radio-resistance. It is likely, therefore, that they
can also modulate sensitivity and resistance to anticancer
drugs in substantial ways. However, the mechanisms re-
sponsible for chemotherapy resistance by miRNAs in GC
have not been clearly identified.
MiR-223 has been known to be up-regulated in many
human cancers, including colorectal cancer [25], lung
cancer [26] and GC [27]. Specially, miR-223 was re-
ported to be involved in trastuzumab induced resistance
of GC [13]; however, it is still unclear whether miR-223
play a role in DDP induced resistance. The prognostic
values of miR-223 in human cancers are also investi-
gated [28]. These experimental data, taken together, sup-
port an important role of altered miR-223 during tumor
progression and metastasis. Additionally, miR-223 was
reported to be significantly up-regulated in H. pylori
infected gastric tissues through miRNA array profiling.
We found in the present study that H. pylori positive pa-
tients had a significantly higher proportion of miR-223
over-expression. In this study, we will investigate the
emerging roles of miR-223 in DDP resistance of human
GC cells. By loss-of-function studies, down-regulation of
miR-223 could reverse the in vitro DDP resistance of
DDP-resistant GC cells by affecting G1/S cell cycle tran-
sition and inducing apoptosis enhancement. Meanwhile,
parental GC cell line transfecting with miR-223 mimic
was established for gain-of-function studies. We showed
that up-regulation of miR-223 could reduce the sensitiv-
ity of parental GC cells to DDP in vitro. Likewise, we
also found that up-regulation of miR-223 could affect
G1/S transition and reduce the DDP-induced apoptosis
in parental GC cells. Importantly, to further explore the
molecular mechanisms by which miR-223 exerts its
function, the determination of its functional target gene
is essential. Analyses using the TargetScan, PicTar andmiRanda algorithms’ databases revealed that more than
100 genes were predicted to be the potential targets of
miR-223. According to the functions of these genes and
the effect of miR-223 on GC cells, FBXW7 was chosen
as the interesting gene in further study. Our data clearly
suggest that miR-223 promotes the DDP resistance of
GC cells by directly targeting FBXW7. This conclusion
is based on several pieces of evidence. First, miR-223
inhibitor significantly up-regulates the expression of
FBXW7 mRNA and protein in 7901/DDP cells, whereas
miR-223 mimic significantly down-regulates the expres-
sion of FBXW7 mRNA and protein in 7901 cells. Sec-
ond, the luciferase activity assay indicated that miR-223
could bind the 3’-UTR of the FBXW7 transcript. Third,
overexpression of FBXW7 could mimic the effect of miR-
223 inhibitor in 7901/DDP cells, whereas silencing of
FBXW7 could partially reverse the effect of miR-223 in-
hibitor in 7901 cells. Fourth, down-regulation of FBXW7
could mimic the effect of miR-223 mimic in 7901 cells,
whereas up-regulation of FBXW7 could partially reverse
the effect of miR-223 mimic in 7901/DDP cells. Finally,
FBXW7 was negatively correlated with miR-223 in GC
tissues. These data suggest that miR-223 targets FBXW7
and down-regulates its expression in GC.
FBXW7, also known as F-box and WD repeat domain-
containing 7, has been found to be involved in numer-
ous cellular processes including cell proliferation, apop-
tosis, cell cycle, differentiation and its expression change
is related to tumor prognosis [29,30]. FBXW7 has been
identified as a p53 target gene. In support of this notion,
Fbxw7 was dramatically up-regulated by infection with
adenovirus-mediated transfer of wild-type p53 into the
p53-deficient cells [31]. It is considered as a p53-
dependent tumor suppressor protein and leads to
ubiquitination-mediated suppression of several oncopro-
teins including c-Myc, cyclin E, Notch, c-Jun and others
[32,33]. In our study, however, we did not find c-myc
protein change after FBXW7 transfection. C-myc mRNA
was inhibited after FBXW7 overexpression and increased
after FBXW7 knock down. This is probably due to the
post-transcriptional regulation of the genes. MicroRNAs
(miRNAs) including miR-27 [34], miR-25 [35] and miR-
223 [36] have been reported to be involved in regulating
the expression of FBXW7. Wang et al. reported that
FBXW7 is a potential miR-27a target. Consistently, there
is an inverse correlation between miR-27a expression and
FBXW7 levels in human tumor samples. Lerner et al. fur-
ther discovered that miR-27a suppresses FBXW7 during
specific cell cycle phases [37]. Wertz et al. reported that
FBXW7 inactivation and increased Mcl-1 levels promoted
resistance to anti-tubulin chemotherapeutic agents and
accelerated tumorigenesis. This group also reported that
inhibition of Mcl-1 in FBXW7 null cells restored their
sensitivity to taxol- and vincristine-induced cell death
Zhou et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:28 Page 13 of 14[38]. Collectively, these provided stronger evidence that
the formation of DDP resistant phenotype of GC cells was
mediated via FBXW7 inactivation.
In summary, our data establish a functional link that
miR-223 and FBXW7 in GC, and show that miR-223
could promote DDP resistance in GC cells via regulating
cell cycle and apoptosis by targeting FBXW7. Thus, in the
future, miR-223/FBXW7 signature might predict the re-
sponses of GC patients to DDP-based chemotherapy and
represent potential targets for therapeutic intervention.Additional files
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